Invasive fungal diseases are major complications associated with the treatment of hematologic malignancies. The integration of host-derived biomarkers into clinical processes to predict the risk and progression of fungal disease is a promising approach in immunocompromised patients. Recent insights into human antifungal immunity have highlighted the remarkable infl uence of host genetics in modulating susceptibility to infection. In this chapter, we describe protocols to examine human genetic variation and to assess its functional consequences using the pattern recognition receptor PTX3 as an example.
Introduction
Invasive fungal diseases, particularly invasive aspergillosis (IA), are major complications associated with the treatment of hematologic malignancies [ 1 ] . Vaccines are not available, and despite noteworthy recent developments in diagnostic and therapeutic approaches, these diseases remain associated with unacceptable mortality rates [ 2 , 3 ] . Concerns over excessive prescription of antifungal drugs and the remarkable burden these diseases convey to the healthcare systems are inspiring a shift from universal prophylaxis to risk stratifi cation and preemptive approaches. Recent evidence continues to highlight the complexity of the multiple fungal-sensing immune systems and the remarkable infl uence of the host genetics in the ability to control infection risk and its progression. As a result of our improved understanding of the host-fungus interaction , several relevant target genes (and associated genetic variants) with the potential to be exploited in future personalized medical interventions in high-risk settings based on individual genetic risk have been identifi ed.
Chronic granulomatous disease and autosomal-dominant hyper-IgE syndrome (AD-HIES) are the most common examples of primary immunodefi ciencies typically associated with susceptibility to IA [ 4 ] . These severe immune defi ciencies with monogenic inheritance are usually limited to a very small number of individuals or families, but the identifi cation of genetic defects is very informative on immune defense mechanisms. For most individuals however, genetic propensity to fungal disease has a polygenic inheritance, acting in concert with other clinical predisposing variants such as chemotherapy-induced neutropenia. Our increasing ability to analyze human variability at the DNA level has made possible the identifi cation of several host genetic variants amenable to use in the categorization of patients with a high risk of infection and to target antifungal therapy (reviewed in [ 5 , 6 ] ). However, the clinical translation of this active fi eld of research is still limited, mostly due to the heterogeneity of cohorts, sample size, case and control selection bias, and statistical misconceptions.
Among the most encouraging examples reported to date, a donor haplotype in Toll-like receptor 4 (TLR4) underlying a delayed T cell and natural killer T cell immune reconstitution [ 7 ] has been disclosed as an important risk factor for developing IA in recipients of allogeneic hematopoietic stem cell transplantation (HSCT) [ 8 ] . In addition, TLR4 variants have been previously linked with chronic aspergillosis in immunocompetent individuals [ 9 ] and fungal colonization in HSCT recipients [ 10 ] . However, and since the fungal ligand (or the host-derived molecule released in response to fungal infection ) for TLR4 remains debated, uncovering the exact mechanism(s) through which TLR4 defi ciency impacts antifungal immunity is required to strengthen the prognostic signifi cance of its genetic variation.
It is noteworthy that, in addition to TLR4, genetic variation in other TLRs has also been proposed to infl uence the risk of IA. For example, a regulatory variant decreasing the expression of TLR3 in dendritic cells was found to impair the recognition of fungal nucleic acids and to compromise the effi cient priming of protective memory CD8+ T cell responses, thereby rendering HSCT recipients more prone to develop IA [ 11 ] . Ultimately, the evaluation of regulatory variation impacting adaptive immunity might help to enhance the discriminatory potential of recent immunodiagnostic strategies based on the evaluation of fungal-specifi c adaptive immune responses [ 12 ] . Of interest, damage perception is coupled with pathogen-sensing pathways (especially intracellular TLRs) to restrain infl ammation in experimental aspergillosis [ 13 ] . Therefore, it is not surprising that genetic variants determining a hyperactivation in danger signaling axes, and presumably underlying exuberant infl ammatory responses, were also found to increase the risk for IA [ 14 ] . Finally, other examples include genetic variants in TLR1 and TLR6 [ 15 ] , and TLR5 [ 16 ] , but further studies are warranted to defi nitely assure their predictive potential for fungal disease.
Dectin-1 defi ciency has consistently been reported to contribute to susceptibility to IA [ 17 -19 ] . In particular, a stop codon polymorphism in Dectin-1 ( CLEC7A ) compromising the surface expression of the receptor in myeloid cells and downstream cytokine production in response to fungal infection [ 20 ] signifi cantly increased the risk of IA in HSCT recipients [ 18 ] . The fact that Dectin-1 defi ciency in both transplant counterparts synergized towards risk of IA highlighted for the fi rst time the pivotal contribution of non-hematopoietic Dectin-1 in antifungal immunity . The prominent biological plausibility of this association suggests Dectin-1 as an attractive candidate not only in risk stratifi cation measures but also in immunotherapeutic strategies aiming at countering the defective Dectin-1 function.
Numerous positive associations between genetic variants in cytokine and chemokine genes and risk of IA have also been reported [ 21 -26 ] . Most of these initial reports were however largely underpowered and performed in poorly characterized cohorts, thereby precluding defi nite conclusions about genetic variants affecting cytokine production in the context of IA. There are however some exceptions that assume particular relevance given the robust study design and functional validation [ 22 , 27 ] . Among the exceptions, a haplotype in C-X-C motif ligand 10 (CXCL10) was mechanistically correlated to a defi cient expression of this chemokine in dendritic cells and, accordingly, high levels of CXCL10 were also more frequently observed among patients surviving IA compared to unaffected controls [ 22 ] . More recently, variants in the genes encoding for IL-1β and beta-defensin 1 (DEFB1) were reported to increase the risk of IA in solid organ transplant recipients, supposedly by impairing fungal-induced proinfl ammatory cytokine secretion by mononuclear cells [ 27 ] .
Next-generation sequencing technologies now provide exciting possibilities to pin down essential steps in the host-fungus interaction at a level of complexity previously unanticipated. The fi rst genome-wide association studies (GWAS) exploring host susceptibility to IA are underway and are expected to provide unbiased insights into the genetic defects contributing to development of IA. The plausibility of these approaches has been recently demonstrated in invasive fungal diseases, in which functional genomics analyses have allowed the identifi cation of new important players controlling susceptibility to candidemia [ 28 , 29 ] . Finally, genetic analysis of gene expression represents another powerful approach enabling insights into the human genomic landscape by generating expression maps that might be revealed extremely useful for the functional interpretation of noncoding variants likely to arise from ongoing genome-wide initiatives [ 30 ] .
A number of alternative strategies using mouse models of infection as a starting point have also been employed to defi ne candidate genes involved in susceptibility to IA [ 31 , 32 ] . Genetic mapping analysis of survival data of animals subjected to experi-mental infection led to the identifi cation of a non-synonymous polymorphism in human plasminogen (PLG), a regulatory molecule with opsonic properties, as an important modulator of susceptibility to IA in humans [ 32 ] . Genetic defi ciency of additional molecules with opsonic activity-e.g., mannose-binding lectin (MBL) [ 33 ] and the long pentraxin 3 (PTX3) [ 34 ] -has also been disclosed as a major determinant of susceptibility to IA, pointing to a key contribution of the innate humoral arm to an adequate activation of protective antifungal immune responses. This is corroborated by the validation of the association of a PTX3 haplotype and increased risk of IA in two independent, high-powered genetic association studies [ 34 , 35 ] . The involved haplotype was found to compromise the alveolar availability of PTX3 and, at a cellular level, its expression during the developmental programming of neutrophil precursors in the bone marrow, leading to defective antifungal effector mechanisms of newly reconstituted neutrophils [ 34 ] . Importantly, this association was also recently replicated in recipients of lung transplant [ 36 ] , highlighting a potential applicability of these markers in predicting infection across patients with intrinsically different predisposing conditions. Of interest, the alveolar levels of PTX3 have been demonstrated to discriminate microbiologically confi rmed pneumonia in mechanically ventilated patients [ 37 ] . Given that these levels vary individually according to host genotypes [ 34 ] , we can envisage the quantifi cation of PTX3 in bronchoalveolar lavage fl uids as a complementary surveillance measure in addition to the currently available diagnostic approaches. Finally, the fact that exogenous administration of PTX3 is able to revert the genetic defect in vitro [ 34 ] further highlights the potential of PTX3-based immunotherapies to treat (or prevent) IA [ 38 ] .
Although the overall weight of the antifungal immune response is certainly driven by adding effects of single genetic factors and their complex interactions with clinical immune dysfunctions, PTX3 represents the most robust genetic marker identifi ed to date. These consistent fi ndings are expected to lay the foundations for well-designed prospective trials ultimately endorsing PTX3-based genetic testing in risk stratifi cation approaches for IA. In this chapter, we will use PTX3 as an example to describe protocols to assess genetic variation in PTX3 associated with susceptibility to IA, and to evaluate the associated functional consequences in circulating neutrophils from patients at-risk.
Materials
Prepare all solutions using ultrapure water and cell-culture grade reagents. Prepare and store all reagents at room temperature (unless indicated otherwise). Carefully follow all waste disposal regulations when disposing of human waste materials. 
Methods
For the purpose of this chapter, genetic variants in PTX3 are given as examples of common variants that have been described to infl uence the risk of IA; however, these can be replaced with other known and novel genetic markers. The methods addressing the functional consequences of these variants and described below have been verifi ed in human circulating neutrophils.
Reagents used to isolate genomic DNA are part of the QuickgDNA ™ MiniPrep Kit. By using the innovative Zymo-Spin™ Column technology, this kit yields highly purifi ed RNA-free DNA, bypassing the need for RNase A treatment and excluding the use 
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of proteinase K and organic denaturants, thereby ensuring high quality for sensitive downstream applications, including SNP analysis . In addition, all reagents are compatible with commonly used anticoagulants (i.e., EDTA, heparin, citrate) in blood drawing procedures. Additional equipment required includes a microcentrifuge and a vortex.
1. Add 400 μL of lysis buffer to 100 μL of whole blood (4:1).
Mix thoroughly by vortexing and allow the mixture to rest for 5-10 min at room temperature ( see Note 1 ).
2. Transfer the mixture to a Zymo-Spin ™ column in a collection tube and centrifuge at 10,000 × g for 1 min.
3. Wash the column with 200 μL of DNA pre-wash buffer and centrifuge as before.
4. Add 500 μL of DNA wash buffer to the column and centrifuge as before.
5. Elute the DNA in 50 μL of elution buffer and collect the purifi ed DNA in a clean microcentrifuge tube ( see Note 2 ).
6. Determine the concentration of DNA in each sample by light spectrophotometry (e.g., NanoDrop) using the elution buffer as blank.
The Kompetitive Allele-Specifi c PCR (KASPar) chemistry (LGC Genomics) is hereafter used as an example of a commercial ondemand assay to perform genotyping. This kit contains a KASP™ Assay Mix that is specifi c to the SNPs under analysis and consists of two competitive, allele-specifi c forward primers and one common reverse primer. Each forward primer incorporates an additional tail sequence that corresponds with one of two universal fl uorescent resonance energy transfer (FRET) cassettes (FAM and HEX) present in the KASP™ Master Mix. This mix also includes the ROX™ passive reference dye, Taq polymerase, free nucleotides, and MgCl 2 in an optimized buffer solution.
1. Vortex thoroughly all the components of the KASPar assay prior to use.
2. Dispense 5 μL of each DNA sample onto a qPCR-compatible 96-well plate ( see Note 3 ). Make sure to include at least three non-template controls (NTC) containing ultrapure water.
3. Prepare a master mix containing 5 μL of 2× reaction mix and 0.14 μL of the primer mix for each sample to be analyzed .
4. Add 5 μL of the master mix to each DNA and NTC well.
5. Seal the 96-well plate carefully and run the qPCR in a compatible instrument according to the following thermal profi le ( see Notes 4 and 5 ). 6. Perform the allelic discrimination by reading fl uorescence at 25 °C (Fig. 1 ). 7. In the event clear genotyping clusters are not observed, the plate should be thermally cycled further (three additional cycles of 20 s at 94 °C and 60 s at 57 °C) and read again at 25 ° C .
Genotyping of PTX3 SNPs
1. Dilute the collected whole blood at a 1:4 proportion with 0.9 % NaCl.
2. Layer 10 mL of Histopaque 1077 beneath the diluted whole blood using a pipette or a syringe ( see Note 6 ).
3. Centrifuge at 400 × g for 40 min at 20 °C without brake ( see Note 7 ).
4. Aspirate and discard the supernatant and resuspend the granulocyte/red blood cell (RBC) pellet in 20 mL of PBS.
5. Add an equal volume of dextran/saline solution, mix and incubate in the upright position for approximately 30 min at room temperature. 6. Aspirate and save the leukocyte-rich plasma (upper layer) using a pipette.
Isolation of Circulating Neutrophils
7. Pellet cells from the plasma by centrifuging at 250 × g for 10 min at 4 °C ( see Note 8 ).
8. To remove residual RBC, subject cells to hypotonic lysis by resuspending the pellet in 20 mL of cold 0.2 % NaCl for exactly 30 s.
9. Restore isotonicity by adding 20 mL of ice-cold 1.6 % NaCl.
10. Centrifuge at 250 × g for 6 min at 4 °C and discard the supernatant. Repeat steps 8 and 9 until the cell pellet appears free of RBC .
11. Resuspend cells in ice-cold PBS and determine cell concentration by counting in a Neubauer chamber.
1. Transfer 10 6 neutrophils into an Eppendorf tube and remove the supernatant by centrifuging at 250 × g for 6 min at 4 °C.
2. Add 200 μL of lysis buffer and incubate 5 min on ice.
3. Collect the cell lysate by centrifugation at 12,000 × g for 15 min at 4 °C.
4. Store at −80 °C until the determination of intracellular PTX3 by ELISA .
All reagents from the ELISA kit for PTX3 should be brought to room temperature before use and the reconstituted components should be allowed to sit for at least 15 min with gentle agitation. Working dilutions should be prepared according to the manufacturer's instructions and used immediately.
1. Dilute the capture antibody to the working concentration using PBS and coat a 96-well microplate with 100 μL per well.
2. Seal the plate and incubate overnight at room temperature.
3. Wash each well three times with 400 μL of wash buffer ( see Note 9 ).
4. Block the plate by adding 300 μL of reagent diluent to each well and incubate for 1 h at room temperature. Repeat the washing step as above.
5. Add 100 μL of sample (it may be necessary to dilute the samples prior use) or standards in reagent diluent per well. Cover the plate with an adhesive strip and incubate overnight at 4 °C.
6. Repeat the washing step as above.
7. Add 100 μL of the diluted detection antibody to each well and incubate for 2 h at room temperature.
8. Repeat the washing step as above . 11. Repeat the washing step as above.
Preparation
12. Add 100 μL of substrate solution to each well and incubate at room temperature for 20 min ( see Note 11 ).
13. Add 50 μL of stop solution to each well and gently tap the plate to ensure thorough mixing.
14. Determine the optical density of each well immediately using a microplate reader set to 450 nm ( see Note 12 ).
1. To estimate phagocytic activity, plate 5 × 10 5 freshly isolated neutrophils in 12 mm glass coverslips coated with serum proteins or purifi ed fi brinogen in a 24-well plate.
2. Add live FITC-labeled conidia of A. fumigatus at an effector to fungal cell ratio of 1:5 in a fi nal volume of 500 μL ( see Note 13 ).
3. Incubate at 37 °C for 1 h in a humidifi ed CO 2 culture chamber.
4. After incubation, remove the non-adherent conidia by washing carefully twice with PBS.
5. Add 300 μL of trypan blue (1 mg/mL in PBS) to each well for 15 min at 25 °C to quench the fl uorescence of bound but uningested conidia.
6. Wash twice with PBS and fi x the cells in 1 % paraformaldehyde for 15 min.
7. Mount coverslips with the cell side down onto microscope slides in 90 % glycerol in PBS, and seal with clear nail polish.
8. Quantify phagocytosis via phase contrast and fl uorescence microscopy by counting at least 200 neutrophils per coverslip ( see Note 14 ).
1. Incubate neutrophils with conidia of A. fumigatus at an effector to fungal cell ratio of 10:1 for 120 min in a fi nal volume of 100 μL in 96-well fl at-bottomed microtiter plates.
2. After incubation, freeze plates at −80 °C and rapidly thaw at 37 °C to lyse cells and harvest conidia.
3. Prepare serial dilutions (1:10) from each well in PBS (900 μL) and plate 100 μL onto Sabouraud dextrose agar plates. 
Notes
1. It is recommended to add β-mercaptoethanol to the genomic lysis buffer at a fi nal dilution of 0.5 % (v/v) to improve lysis performance.
2. Ensure that the elution process occurs for at least 1 min to increase the DNA yield.
3. The use of at least 20 ng of DNA in each genotyping reaction is recommended. Use an identical DNA concentration for all samples in order to adequately normalize the fl uorescence intensity.
4. The thermal profi le presented is a typical example that has been specifi cally provided by the manufacturer with some minor modifi cations. Because of the underlying chemistry mechanisms of KASPar, the post-PCR read should always be performed below 40 °C.
5. An optimal cluster visualization is typically obtained using a 7500 Fast qPCR system (Applied Biosystems) and a post-PCR read at 25 ° C .
6. Take care to preserve the interface between the Histopaque and the diluted blood solution, thereby avoiding contamination between both phases.
7. The temperature of 20 °C is crucial to achieve the best cell separation performance.
8. After separation, cells should be kept on ice at all times and handled gently to prevent damage or undesired activation of neutrophils.
9. Complete removal of liquid from the wells by inverting the plate and blotting it against clean paper towels is essential for an optimal performance of the ELISA test.
10. Avoid exposing the plate to light.
11. The length of incubation may vary depending on the concentration of PTX3 . For that reason, check the plate every 5 min and stop the reaction earlier, if necessary.
12. If wavelength correction is available, set it to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm in order to correct for optical imperfections in the plate.
13. For the staining of live conidia of A. fumigatus , incubate 2 × 10 7 conidia in 2 mL of Na 2 CO 3 50 mM buffer, pH 10.2 with FITC at a fi nal concentration of 0.1 mg/mL (prepared in the same buffer) at 37 °C for 4 h. Wash the conidia thoroughly to eliminate residual FITC.
14. Enumerate the number of ingested conidia, or bound but not ingested. The data is typically presented as the percentage of neutrophils ingesting one or more conidia.
15. Calculate the inhibition of CFU-also known as fungicidal activity-using the following formula: % fungicidal activity = (1− X / C ) × 100 where X is the number of CFU obtained after infection of neutrophils, and C is the number of CFU in the absence of neutrophils. Perform three biological replicates for each condition and at least two technical replicates .
